New combo therapy aims to slow liver and lung cancers

NCT ID NCT04563338

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before and after treatment. Researchers hope this combination can boost the immune system to fight these cancers more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and bevacizumab
What this could lead to: If successful, this could point toward a more effective treatment combination for liver cancer and lung cancer that has spread to the liver.
What could go wrong: This is a small, early-phase study with only 36 participants, so results may not apply broadly. The drugs can cause immune-related side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIVER METASTASES NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.